ENGlioblastoma treatment in Germany combines surgery, radiotherapy and chemotherapy planned by one specialist team, and for a family facing this diagnosis, time matters. It often starts suddenly, with a seizure, severe headaches or changes in speech; an MRI scan shows a tumour, and the report mentions glioblastoma. Relatives then need to understand the next steps quickly.
In Germany, glioblastoma is treated at neuro-oncology centres where a neurosurgeon, radiation oncologist, neurologist and oncologist work as one team. This page covers how the diagnosis is confirmed, surgery, radiotherapy and chemotherapy, recurrence and where treatment takes place; other tumour types are covered on the general page about brain tumours.
What glioblastoma is and how the diagnosis is confirmed
Glioblastoma is the most aggressive tumour arising from glial cells, the cells that support and nourish the brain’s neurons. In the World Health Organization classification of central nervous system tumours, it is a grade 4 glioma, the highest grade. It grows fast and infiltrates the surrounding tissue, so unlike tumours in other organs it cannot be removed «with a margin»: single tumour cells almost always stay behind. Some reports still use the older full name, glioblastoma multiforme (GBM): it is the same tumour, and glioblastoma multiforme treatment in Germany follows the same standard.
The diagnosis is suspected on a contrast MRI and confirmed by examining tissue from surgery or a biopsy. The pathologist also tests two molecular markers. An IDH mutation decides the name: only a tumour without it is called glioblastoma, while a tumour with the mutation is classed as an astrocytoma. MGMT promoter methylation switches off the gene for an enzyme that repairs chemotherapy damage in tumour DNA, so the tumour usually responds better to temozolomide. How these markers guide treatment is set out in the glioma guideline of the German Society of Neurology, which is currently being revised.
Surgery: removing as much as possible while protecting speech and movement
The goal is to remove as much tumour as can be removed safely, without new problems with speech or movement. A lost brain function is hard to regain, whereas remaining tumour cells are treated with radiotherapy and chemotherapy. The extent of removal still shapes further treatment, so an MRI shortly after the operation shows how much tumour is left.
Three tools help the surgeon. Neuronavigation works like a GPS based on MRI images, showing where the instrument is in relation to the tumour and vital brain areas. Intraoperative monitoring uses weak electrical pulses to check the motor pathways while the surgeon works. For fluorescence, the patient drinks a solution of 5-aminolevulinic acid a few hours before surgery, and under the blue light of the microscope the tumour tissue glows red.
If the tumour lies next to the speech area, surgery is sometimes performed with the patient awake: the brain itself feels no pain, and while the patient talks to a neurologist or neuropsychologist and names pictures, the surgeon sees which tissue must be spared. If the tumour cannot be reached, for example deep in the brain, only a biopsy is taken through a small opening.
Radiotherapy and chemotherapy after surgery
After surgery, GBM treatment in Germany follows a clear standard: radiotherapy combined with temozolomide, a chemotherapy drug taken as capsules, then several cycles of temozolomide alone. The radiation covers the tumour area with a margin where cells may have spread. For older or frail patients the radiotherapy course is shortened. The duration and the number of cycles are decided by the hospital’s tumour board.
Tumour Treating Fields, or TTFields, are an additional option. Electrode pads on the shaved scalp, connected to a portable device, create a weak alternating electric field that disrupts tumour cell division. Treatment starts after radiotherapy, alongside the temozolomide cycles, and the device must be worn for most of the day; in a large trial this combination extended survival compared with temozolomide alone. Among others, Prof. Friederike Schmidt-Graf, chief physician of neurology at München Klinik Bogenhausen, works in neuro-oncology including TTF therapy.
Recurrence and clinical trials
Glioblastoma treatment options in Germany when the tumour comes back include a second operation, re-irradiation or a different drug regimen, because glioblastoma almost always returns. Treatment extends life and helps preserve its quality, but it does not promise a cure. The choice depends on where the tumour has recurred, how long ago the first treatment ended and the patient’s condition; with no single standard, each case is decided individually.
University centres run clinical trials of new drugs and vaccines. Patients can join only if they meet strict eligibility criteria, such as tumour type, molecular markers, previous treatment and general condition, and the study team decides, not the patient or an agent. Paid «experimental» methods outside trials are another matter: their benefit is unproven, and with glioblastoma time is precious.
Immunotherapy is what families ask about most and what agents advertise most. Four approaches are being studied: checkpoint inhibitors, which release the immune system’s «brakes»; dendritic cell vaccines made from the patient’s own immune cells; CAR-T cells, the patient’s lymphocytes reprogrammed against the tumour; and oncolytic viruses, which destroy tumour cells. All of these are being tested in clinical trials: they are not part of standard glioblastoma treatment, and there is no reliable proof yet that they extend life. If such a method is offered for a fee outside a trial, ask which study tested it and discuss the offer with the neuro-oncology tumour board.
Where glioblastoma is treated in Germany
Glioblastoma is treated at neuro-oncology centres of university and major hospitals; here are a few examples, in no particular order. At Klinikum rechts der Isar of the Technical University of Munich, the Department of Neurosurgery is headed by Prof. Bernhard Meyer, with brain tumour surgery and clinical neuro-oncology among its focus areas. At Helios Klinikum Erfurt, neurosurgeon Prof. Rüdiger Gerlach has led the neuro-oncology centre since 2015, with neurologist Prof. Andreas Steinbrecher as his deputy.
At University Hospital Essen, Prof. Ulrich Sure has headed the Department of Neurosurgery since 2008; his work includes brain tumour surgery and research on intraoperative imaging, which shows the surgeon the tumour during the operation. What matters most is not a hospital’s fame but a well-coordinated team and a quick start of treatment.
Frequently asked questions
Where is the best place to go for glioblastoma?
The best place is a neuro-oncology centre where a tumour board, not a single doctor, plans treatment; no hospital is right for everyone. Look for certification as a neuro-oncology centre by the German Cancer Society, a tumour board of all the relevant specialists, access to clinical trials and TTFields, and a short wait for surgery and radiotherapy.
What is the most promising treatment for glioblastoma?
The treatment with the strongest evidence is the standard: removing as much tumour as possible, then radiotherapy with temozolomide and further temozolomide cycles, sometimes with TTFields. New drugs, vaccines and cell therapies are tested in clinical trials, where the most promising ideas are today. A trial is worth discussing with the tumour board; a promised cure is a reason for caution.
Can glioblastoma be cured?
As a rule, no: treatment extends life and helps patients stay independent for longer, but the tumour almost always returns. The time gained depends on age, general condition, the extent of removal and markers such as MGMT methylation. Discussing the prognosis openly with the doctor helps the family plan not only treatment but also life.
How AlenMed arranges glioblastoma treatment in Germany
AlenMed collects and translates the documents, submits them to the neuro-oncology tumour board of a partner hospital and organises the trip. The hospital needs the MRI discs in DICOM format (not just the reports), tissue blocks and slides for review and molecular testing, discharge summaries and a list of current medication. If the family has doubts about the diagnosis or plan, a second opinion is possible before travelling.
AlenMed also arranges the visa invitation and an interpreter at consultations, coordinates the dates of surgery and radiotherapy and, after discharge, helps with neurological rehabilitation. The AlenMed office is in Munich; partner hospitals are across Germany. The hospital invoices directly and sends a cost estimate before the trip; what makes up brain tumour treatment costs is explained on a separate page.
This material is for reference only and is not an offer. Treatment is decided by a doctor at an in-person consultation.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
